Reply

Affiliations

¹ National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD.
² Oregon Health & Science University, Portland, OR.
³ University of Texas Health Sciences Center at Houston.
⁴ Denver Veterans Affairs Medical Center and University of Colorado, Aurora, CO.

Comment

Michael M Ward et al. Arthritis Rheumatol. 2016 Jun.

. 2016 Jun;68(6):1563-4.

doi: 10.1002/art.39524.

¹ National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD.
² Oregon Health & Science University, Portland, OR.
³ University of Texas Health Sciences Center at Houston.
⁴ Denver Veterans Affairs Medical Center and University of Colorado, Aurora, CO.

No abstract available

Comment on

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, Borenstein D, Hiratzka J, Weiss PF, Inman RD, Majithia V, Haroon N, Maksymowych WP, Joyce J, Clark BM, Colbert RA, Figgie MP, Hallegua DS, Prete PE, Rosenbaum JT, Stebulis JA, van den Bosch F, Yu DT, Miller AS, Reveille JD, Caplan L. Ward MM, et al. Arthritis Rheumatol. 2016 Feb;68(2):282-98. doi: 10.1002/art.39298. Epub 2015 Sep 24. Arthritis Rheumatol. 2016. PMID: 26401991 Free PMC article.
Treatment of Patients With Nonradiographic Axial Spondyloarthritis Who Have Negative Magnetic Resonance Imaging Results and Normal C-Reactive Protein Levels at Baseline: Comment on the Article by Ward et al.
Akkoc N, Khan MA. Akkoc N, et al. Arthritis Rheumatol. 2016 Jun;68(6):1563. doi: 10.1002/art.39525. Arthritis Rheumatol. 2016. PMID: 26637122 No abstract available.

1. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189–94. - PubMed
1. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–86. - PubMed
1. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) Ann Rheum Dis. 2013;72:815–22. - PMC - PubMed
1. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66:2091–102. - PubMed
1. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39–47. - PMC - PubMed